



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – Highlights of Changes in Protocols, Pre-Printed Orders and Patient Handouts: Cardiotoxicity Associated with Fluoropyrimidines, Revised Laboratory Monitoring in Rituximab-Containing Lymphoma Chemotherapy Protocols
- **Compassionate Access Program** – Pearls for CAP Users
- **Continuing Professional Development** – Reminder: National Oncology Pharmacy Symposium 2013
- **Cancer Drug Manual** – Revised: Capecitabine, Methotrexate
- **Benefit Drug List** – Revised: BRAJACTW, BRLAACTW, GOOVDDCAT
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: UGIGAJCPRT; Revised: BMTLPDRIT, BRAJACTW, BRLAACTW, CNAJZRT, CNTEMOZ, GIAVCETIR, GOOVDDCAT, UGUPABI, LYCHOPR, LYCODOXMR, LYCVPR, LYGDPR, LYIVACR, ULYRICE, LYRITZ; Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine: BRAJCAFPO, BRAJCMF, BRAJCMFPO, BRAJDTFEC, BRAJFEC, BRAJFECF, BRAVCAF, BRAVCMF, BRINFCEF, UBRFACEF, GIAJCAPOX, UGIAVTZCAP, UGICAPIRI, UGICAPOX, GICART, UGICIRB, UGICOXB, GICPART, UGIGAJCC, UGIGAVCCT, GIGAVECC, GIGECC, GIRAJCOX, HNAVFUP, UHNLADCF, HNAVFUP
- **Website Resources and Contact Information**

EDITOR'S CHOICE

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

Cardiotoxicity Associated with Fluoropyrimidines:

The precautions section on a number of BCCA Patient Handouts has been updated to cover cardiotoxicity associated with fluorouracil and capecitabine (see [Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts](#) table below). The associated BCCA chemotherapy *protocols* were already revised with these precautions in May 2013. For more information on fluoropyrimidine-associated cardiotoxicity, please see the [May 2013](#) issue of the Systemic Therapy Update.

Revised Laboratory Monitoring Recommendations in Rituximab-Containing Lymphoma Chemotherapy Protocols:

The requirement to omit rituximab from the first cycle of chemotherapy in BCCA lymphoma protocols if the peripheral blood lymphocyte count was above $30 \times 10^9/L$ (to reduce the risk of cytokine release syndrome) has been removed. At the time these protocols were first implemented, experience with rituximab was limited. However with more available data from clinical trials, the risk of cytokine release syndrome appears to be quite low, so there is no reason to uniformly withhold rituximab based on the lymphocyte count. Although low, the risk of cytokine release syndrome is still increased when the peripheral blood lymphocyte count is greater than $30-50 \times 10^9/L$. Therefore the option remains for

EDITOR'S CHOICE

clinicians to pre-medicate such patients with steroids prior to rituximab infusion or omit rituximab from the first cycle of treatment. Please see the [Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts](#) table below for all affected protocols.

COMPASSIONATE ACCESS PROGRAM

PEARLS FOR CAP USERS

As part of the ongoing quality improvement process, the Compassionate Access Program (CAP) will be providing periodic updates and practical suggestions for CAP users in the Systemic Therapy Update.

Below are some pearls intended to improve the CAP user experience and turnaround times:

- References are NOT required for routine requests where the patient meets the eligibility criteria of an existing BCCA undesignated protocol (i.e. protocols that start with "U").
- References are also NOT required when a similar well-referenced CAP request was previously approved – please indicate the previous CAP request number on the new application.
- Drugs in the drop-down menu have now been updated to improve the accuracy of drug selection.
- When requesting addition of a drug to an existing BCCA approved regimen, all of the drugs should be listed in the CAP request (i.e. if the request is to add bevacizumab to carboplatin/paclitaxel, all three drugs should be entered, not just bevacizumab).
- Submit appeals directly using the regular CAP application process by indicating the original CAP request number, and entering additional information and references in the "rationale" section.

Feedback on the CAP review process is always welcomed. Please email the CAP office at cap_bcca@bccancer.bc.ca.

CONTINUING PROFESSIONAL DEVELOPMENT

REMINDER: NATIONAL ONCOLOGY PHARMACY SYMPOSIUM (NOPS) 2013

Please be reminded that the early bird deadline for NOPS 2013 registration is September 16, 2013.

Date: November 14-17, 2013

Location: Hyatt Regency Vancouver, Vancouver, BC

Website: <http://www.capho.org/nops-2013>

NOPS 2013 will be held in beautiful VANCOUVER! NOPS is the leading edge annual educational event produced by the Canadian Association of Pharmacy in Oncology (CAPHO). The theme to this year's conference is "Many Paths, Many Journeys". Please visit the conference website for details about the program and speakers.

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Capecitabine Patient Handout:

- *Emergency section* – revised caution about cardiac toxicity to be consistent with the fluourouracil handouts

Methotrexate Monograph:

- *Pharmacokinetics table* – added 7-hydroxy-methotrexate as an active metabolite
- *Interactions table* – updated omeprazole interaction in response to Health Canada warning
- *Dosing section* – added information about metronomic dosing to the Oral Dosing and Dosage in Renal Failure sections to reflect the BRAVCMPO protocol

BENEFIT DRUG LIST

REVISED PROGRAMS

The following programs have been revised on the Benefit Drug List effective 01 September 2013:

Protocol Title	Protocol Code	Benefit Status
Adjuvant Therapy for Early Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by Weekly PACLitaxel	BRAJACTW	Class I
Locally Advanced Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by Weekly PACLitaxel	BRLAACTW	Class I
Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using CARBOplatin and Weekly PACLitaxel	GOOVDDCAT	Class I

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UGIGAJCPT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Chemotherapy of Stomach Cancer Patients with Completely Resected Stomach Cancer Using Cisplatin, Capecitabine and Radiation Therapy

REVISED PROTOCOLS, PPPOS AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BMTLPDRIT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Pre-Emptive ritUXImab Therapy of Epstein-Barr Virus (EBV) Related Post-Transplant Lymphoproliferative Disease
BRAJACTW	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement deleted from Eligibility, Protocol Code updated, Drug Names reformatted, cyclophosphamide dilution clarified under Treatment section</i>	Adjuvant Therapy for Early Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by Weekly PACLitaxel
BRLAACTW	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>CAP requirement deleted from Eligibility, Protocol Code updated, Drug Names reformatted, cyclophosphamide dilution clarified under Treatment section</i>	Locally Advanced Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by Weekly PACLitaxel
CNAJZRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section reformatted</i>	Concomitant and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas
CNTEMOZ	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section reformatted</i>	Therapy for Malignant Brain Tumours using Temozolomide
GIAVCETIR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Liver function tests clarified under Tests section, Drug Name reformatted</i>	Third Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan
GOOVDDCAT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement deleted from Eligibility, Protocol Code updated</i>	Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using CARBOplatin and Weekly PACLitaxel
UGUPABI	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>PSA requirement clarified on Return Appointment Orders</i>	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and Prednisone
LYCHOPR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Revised statement on peripheral blood lymphocyte count, Drug Name reformatted</i>	Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine, predniSONE and ritUXImab (CHOP-R)
LYCODOXMR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Revised statement on peripheral blood lymphocyte count, Drug Name reformatted</i>	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRIStine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and ritUXImab
LYCVPR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Revised statement on peripheral blood lymphocyte count, Drug Name reformatted, Contact Physician updated</i>	Advanced Indolent Lymphoma using Cyclophosphamide, vinCRIStine, predniSONE and ritUXImab (CVP-R)

REVISED PROTOCOLS, PPPOS AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
LYGDPR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Revised statement on peripheral blood lymphocyte count, Drug Name reformatted</i>	Treatment of Lymphoma with Gemcitabine, Dexamethasone and CISplatin (GDP) with riTUXimab
LYIVACR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Revised statement on peripheral blood lymphocyte count, Drug Name reformatted</i>	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and riTUXimab
ULYRICE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Revised statement on peripheral blood lymphocyte count, Drug Name reformatted</i>	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXimab
LYRITZ	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Revised statement on peripheral blood lymphocyte count, Drug Name reformatted</i>	Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for Ibritumomab ⁹⁰ Y (ZEVALIN®)

Precautions on cardiac toxicities have been updated for the following fluorouracil- and capecitabine-containing Patient Handouts:

CODE	Protocol Title
BRAJCAFPO	Adjuvant Therapy for Breast Cancer using Oral Cyclophosphamide, DOXOrubicin and Fluorouracil
BRAJCMF	Adjuvant Therapy for High Risk Breast Cancer Using Cyclophosphamide (IV), Methotrexate and Fluorouracil
BRAJCMFPO	Adjuvant Therapy for High Risk Breast Cancer Using Cyclophosphamide (Oral), Methotrexate and Fluorouracil
BRAJDTFEC	Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Trastuzumab, and Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFEC	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFECd	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BRAVCAF	Palliative Therapy for Metastatic Breast Cancer Using Cyclophosphamide, DOXOrubicin and Fluorouracil
BRAVCMF	Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide, Methotrexate and Fluorouracil
BRINFCEF	Therapy for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil
UBRLACEF	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine
UGIAVTZCAP	Palliative therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine
UGICAPIRI	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuitable for G1OLFIRI
UGICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine

CODE	Protocol Title
GICART	Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy
UGICIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine
UGICOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
GICPART	Combined Modality Therapy for Carcinoma of the Anal Canal using CISplatin, Capecitabine and Radiation Therapy
UGIGAJCC	Adjuvant chemotherapy treatment of stomach cancer patients with D2 resection (node negative), or for those ineligible for adjuvant chemoradiation, using Cisplatin and Capecitabine
UGIGAVCCT	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Capecitabine and Trastuzumab
GIGAVECC	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, CISplatin and Capecitabine
GIGECC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, CISplatin and Capecitabine
GIRAJCOX	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine
HNAVFUP	Treatment for Advanced Nasopharyngeal Cancer of the Head and Neck using CISplatin and Fluorouracil
UHNLADCF	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Docetaxel, Cisplatin and Infusional Fluorouracil
HNNAVFUP	Treatment for Advanced Nasopharyngeal Cancer of the Head and Neck using 5-Fluorouracil and Cisplatin

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	http://www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 673028		sally.waignein@bccancer.bc.ca
Provincial Systemic Therapy Program	250.712.3900 x 686620		mberk@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Beth Morrison, MLS

Lindsay Schwartz, RN, MScA
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)